Available online on 15.04.2026 at http://ajprd.com

Asian Journal of Pharmaceutical Research and Development

Open Access to Pharmaceutical and Medical Research



Open Access

Review Article

Sustained Release Microspheres in Drug Delivery: Formulation Strategies, Characterization, and Therapeutic Application

Tusara Kanta Behera*, Santosh Kumar Dash, Jyotirmaya Parida, Khagesh Bhoi, Lokesh Kumar Barik, Madhusudan Behera, Jitu Rout, Kandarpa Rana, Kundan Bishi

Department of Pharmaceutics, the Pharmaceutical College, Samleswari Vihar, Tingipali, Barpali, Odisha.

A B S T R A C T

Sustained release microspheres have emerged as a promising and versatile drug delivery system capable of improving therapeutic efficacy, patient compliance, and overall treatment outcomes by providing controlled and prolonged drug release. These microspheres, typically composed of biodegradable and biocompatible polymers such as PLGA, PLA, chitosan, and alginate, are designed to encapsulate a wide range of drugs, including small molecules, peptides, and proteins, and release them at a predetermined rate over extended periods. Various formulation strategies such as solvent evaporation, spray drying, ionic gelation, coacervation, and advanced techniques like microfluidics have been extensively explored to optimize particle size, drug loading, and release characteristics. Comprehensive characterization of microspheres, including particle size analysis, surface morphology, encapsulation efficiency, thermal behavior, and in vitro drug release studies, plays a critical role in ensuring formulation stability and performance. Drug release from microspheres is governed by mechanisms such as diffusion, degradation, swelling, and erosion, which can be effectively, modeled using kinetic approaches like zero-order, Higuchi, and Korsmeyer peppas models. These systems have demonstrated significant potential across diverse therapeutic areas, including cancer therapy, diabetes management, cardiovascular diseases, infectious diseases, hormone delivery, vaccine delivery, and central nervous system disorders, with several formulations already approved for clinical use. Furthermore, recent advancements in targeted delivery, stimuli responsive systems, and nanostructured microspheres, along with integration of Quality by Design (QbD) and artificial intelligence approaches, have further expanded their application scope. Despite challenges such as burst release, scale-up difficulties, and regulatory considerations, sustained release microspheres continue to represent a cornerstone in modern pharmaceutics, offering innovative solutions for controlled and site-specific drug delivery.

Keywords: Sustained release microspheres; Controlled drug delivery; Biodegradable polymers; Drug release kinetics; Therapeutic applications

A R T I C L E I N F O: Received 14 Jan 2025; Review Complete 25 Feb. 2025; Accepted 28 March 2026; Available online 15 April. 2026

Cite this article as:
T K Behera TK, Dash SK, Parida J, Bhoi K, Barik LK, Behera M, Rout J, Rana K, Bishi K, Sustained Release Microspheres in Drug Delivery: Formulation Strategies, Characterization, and Therapeutic Application, Asian Journal of Pharmaceutical Research and Development. 2026; 14(2):163-173, DOI: http://dx.doi.org/10.22270/ajprd.v14i2.1734

*Address for Correspondence:
Tusara Kanta Behera, Assistant Prof. in Pharmaceutics,The Pharmaceutical College, Samleswari Vihar, Tingipali, Barpali, Odisha.

INTRODUCTION

Overview of drug delivery:

Drug delivery systems (DDS) are engineered technologies designed to transport therapeutic agents in the body to achieve a desired therapeutic effect while minimizing side effects. Conventional drug delivery methods, such as oral and parenteral administration, often suffer from limitations including poor bioavailability, rapid drug degradation, fluctuating plasma drug concentrations, and lack of site specificity. To overcome these challenges, advanced drug delivery systems have been developed to control the rate, time, and place of drug release. These systems include sustained release, controlled release, targeted delivery, and novel carrier-based approaches such as nanoparticles, liposomes, microspheres, and hydrogels. Sustained release systems are particularly important as they maintain drug concentration within the therapeutic window for extended periods, thereby improving patient compliance and reducing dosing frequency. The design of an effective DDS depends on multiple factors, including physicochemical properties of the drug, route of administration, pharmacokinetics, and the biological environment at the target site. Recent advancements in nanotechnology and biomaterials have further revolutionized DDS by enabling precise targeting, improved stability, and enhanced therapeutic efficacy,

making them a cornerstone of modern pharmaceutical research and development (1,2).

Need of sustained release formulations

Sustained release (SR) formulations are developed to maintain drug concentrations within the therapeutic window for prolonged periods, thereby overcoming the limitations of conventional dosage forms that often produce fluctuating plasma levels with peaks and troughs. These fluctuations can lead to reduced efficacy or increased toxicity, particularly for drugs with short half-lives or narrow therapeutic indices. By providing controlled and prolonged drug release, SR systems reduce dosing frequency, improve patient compliance, and ensure a more consistent pharmacological response, which is especially important in the management of chronic diseases such as hypertension, diabetes, and cardiovascular disorders. Additionally, SR formulations can enhance bioavailability by extending drug residence time, minimize side effects by avoiding high peak concentrations, and protect drugs from degradation within the gastrointestinal environment. Overall, sustained release systems contribute to improved therapeutic outcomes and optimized drug therapy through better control over drug release and absorption (3).

From a therapeutic perspective, SR systems are particularly beneficial for drugs that require continuous plasma levels, such as analgesics, anti-hypertensives, and anti-diabetic agents. They also reduce total drug consumption and improve the overall efficiency of treatment. Despite these advantages, the development of SR formulations requires careful consideration of drug properties such as solubility, stability, half-life, and dose size, as well as physiological factors affecting drug absorption. Overall, sustained release formulations play a crucial role in modern pharmaceutics by enhancing therapeutic outcomes, improving patient adherence, and optimizing drug therapy (4).

Advantages of microspheres based delivery

Microsphere-based drug delivery systems offer numerous advantages that make them highly suitable for sustained and controlled release applications. One of the key benefits is their ability to provide prolonged and controlled drug release, maintaining therapeutic drug levels over an extended period and reducing dosing frequency. These systems can enhance bioavailability by protecting drugs from enzymatic degradation and improving drug stability, particularly for sensitive molecules such as peptides and proteins. Microspheres also enable targeted and site-specific delivery when modified with ligands or surface coatings, thereby minimizing systemic side effects and improving therapeutic efficacy.

Their small size and large surface area facilitate better drug absorption and uniform distribution in biological systems. Additionally, microspheres can encapsulate both hydrophilic and hydrophobic drugs, offering formulation flexibility. They improve patient compliance due to reduced dosing frequency and can be administered through various routes, including oral, parenteral, and topical. Furthermore, the use of biodegradable and biocompatible polymers such as PLGA ensures safe degradation into non-toxic byproducts, making microspheres a versatile and effective platform in modern drug delivery (5).

Definition & classification

Sustained release microspheres are free-flowing, spherical particulate drug delivery systems typically ranging in size from 1 to 1000 µm, designed to encapsulate therapeutic agents within biodegradable or non-biodegradable polymeric matrices and release them in a controlled manner over an extended period. These systems are developed to maintain consistent drug concentrations in the systemic circulation, reduce dosing frequency, and enhance therapeutic efficacy while minimizing side effects. The drug may be uniformly dispersed within the polymer matrix or confined within a core surrounded by a polymeric shell, depending on the method of preparation and formulation design. The release of drug from microspheres occurs through various mechanisms such as diffusion, polymer degradation, erosion, or a combination of these processes (6).

Microspheres can be broadly classified based on their structure, composition, and functional characteristics. Structurally, they are categorized into microspheres (matrix systems), where the drug is uniformly dispersed throughout the polymer, and microcapsules (reservoir systems), where the drug is enclosed within a distinct core surrounded by a polymeric membrane. Based on composition, they may be biodegradable microspheres (e.g., PLGA, PLA, chitosan), which degrade into non-toxic byproducts within the body, or non-biodegradable microspheres (e.g., polymethyl methacrylate), which require removal after drug release. Functionally, microspheres can be further classified into mucoadhesive microspheres, floating microspheres, magnetic microspheres, and targeted microspheres, each designed to achieve specific therapeutic goals such as prolonged gastric residence, site-specific delivery, or enhanced targeting efficiency. This classification highlights the versatility of microspheres as a platform for sustained drug delivery across a wide range of pharmaceutical applications (7,8).

Mechanism of drug release from microspheres

Drug release from sustained release microspheres is governed by multiple mechanisms that act either independently or in combination to control the release profile. The most common mechanism is diffusion-controlled release, where the drug diffuses through the polymer matrix or pores into the surrounding medium following a concentration gradient, often described by Fick's law. Another significant mechanism is degradation-controlled release, particularly in biodegradable polymers such as poly(lactic-co-glycolic acid) (PLGA), where hydrolytic degradation of polymer chains leads to gradual drug liberation.

Erosion-controlled release also plays a crucial role, where the polymer matrix undergoes surface or bulk erosion, facilitating sustained drug release over time. In hydrophilic systems, swelling-controlled release occurs when the polymer absorbs water, expands, and allows drug molecules to diffuse more easily. Many microsphere systems exhibit a biphasic release pattern, characterized by an initial burst release due to drug present on or near the surface, followed by a prolonged sustained phase governed by diffusion and polymer degradation. The overall release behavior is influenced by factors such as polymer composition, molecular weight, drug loading, particle size, and

environmental conditions like pH and temperature. A thorough understanding of these mechanisms is essential for designing efficient and predictable sustained release microsphere systems (9-11).

Factors influencing drug release

Drug release from microspheres is influenced by a complex interplay of formulation, physicochemical, and environmental factors that collectively determine the rate and mechanism of drug liberation. Polymer-related factors play a dominant role, including polymer type, molecular weight, crystallinity, and degradation rate; for instance, biodegradable polymers like PLGA exhibit release governed by both diffusion and polymer erosion. Drug-related properties such as solubility, molecular weight, and drug–polymer interactions significantly affect release behavior, with highly water-soluble drugs often showing faster diffusion and potential burst release. Particle size and surface area are also critical, as smaller microspheres provide a larger surface area, leading to faster drug release. Additionally, drug loading and distribution within the microsphere influence release kinetics, where higher loading may increase the initial burst effect.

Formulation and process parameters, including method of preparation (e.g., solvent evaporation, spray drying), solvent type, emulsifier concentration, and stirring speed, can alter microsphere morphology and porosity, thereby affecting drug release. Porosity and surface characteristics determine the ease with which the dissolution medium penetrates the matrix and facilitates drug diffusion. Furthermore, environmental conditions such as pH, temperature, and ionic strength of the release medium can impact polymer swelling, degradation, and drug solubility. In biological systems, factors like enzymatic activity and local physiological conditions also contribute to variations in drug release profiles. Understanding and optimizing these factors are essential for achieving desired sustained release characteristics and ensuring reproducible therapeutic performance (9-11).

Scope and objective of this review

This review aims to provide a comprehensive overview of sustained release microspheres as an advanced drug delivery system, with a focus on their formulation strategies, characterization techniques, and diverse therapeutic applications. The scope of the review encompasses the fundamental principles governing microsphere-based delivery, including mechanisms of drug release, selection of suitable polymers, and factors influencing formulation performance. It further covers various preparation methods such as solvent evaporation, spray drying, coacervation, and ionic gelation, along with modern optimization approaches. Emphasis is also placed on physicochemical and in vitro characterization techniques used to evaluate microsphere quality, including particle size analysis, morphology, encapsulation efficiency, and drug release kinetics. Additionally, the review highlights the application of sustained release microspheres in the treatment of chronic diseases, targeted drug delivery, and emerging areas such as stimuli-responsive systems. The objective is to critically analyze recent advancements, identify existing challenges such as burst release and scale-up limitations, and outline future perspectives to guide further research and development in this field (5).

Advantages (12)

- Microspheres provide constant and prolonged therapeutic effect.
- They decrease the dosing frequency and thus improve the patient compliance.
- They could be injected into the body due to the spherical shape for better drug utilization there by it will improve the bioavailability.
- Reduces the frequency or intensity of adverse effects.
- Microsphere a controllable variability in degradation and drug release.
- Reliable means of site specific drug targeting by maintaining the desired concentration at the site of interest without any untoward effect.
- Biodegradable microspheres provide sustained release of drug throughout the particle matrix.
- Target drug to various diseased sites such as targeting of anticancer drugs to the tumour cells.
- The size, surface charge and surface hydrophobicity of microspheres have been found to be an important factor in determining the fate of particles in vivo.

Limitations (13)

Some of the disadvantages were found to be as follows

- The modified release from the formulations.
- The discharge rate of the controlled release dosage form may differ from a range of factors like food and the rate of transit though gut.
- Differences in the release rate from one dose to another.
- Controlled release formulations generally contain higher dose of drug and thus may lead to potential toxicity.
- Dosage forms of this kind should not be crushed or chewed.

Microspheres applicable in different drug delivery systems:

- Ophthalmic Drug Delivery
- Oral drug delivery
- Nasal drug delivery
- Gene delivery
- Intra-tumor and local drug delivery
- Buccal drug delivery
- Gastrointestinal drug delivery
- Transdermal drug delivery
- Peroral drug delivery
- Colonic drug delivery
- Vaginal drug delivery
- Multi-particulate delivery system.

Applications (14)



Classification preview:

Sustained release microspheres can be broadly classified into different types based on their composition and functionality, each providing distinct mechanisms for controlled drug delivery. Biodegradable polymer microspheres**,** typically formulated using polymers such as PLGA, PLA, and PCL, undergo hydrolytic degradation to release the drug in a sustained manner and are widely used in parenteral depot systems (15). In contrast, non-biodegradable microspheres**,** prepared using polymers like ethyl cellulose or polymethyl methacrylate, control drug release primarily through diffusion mechanisms (16). Mucoadhesive microspheres**,** developed with polymers such as chitosan, alginate, and carbopol, adhere to mucosal surfaces, prolonging residence time and enhancing drug absorption (17).

Floating (gastroretentive) microspheres are designed to remain buoyant in gastric fluids, thereby extending gastric residence time and improving bioavailability of drugs with narrow absorption windows (18). Magnetic microspheres incorporate magnetic materials like iron oxide, allowing site-specific targeting under an external magnetic field and reducing systemic side effects (19).

Additionally, hydrogel microspheres**,** composed of hydrophilic polymers, swell upon contact with biological fluids and regulate drug release through diffusion and polymer relaxation (20). Furthermore, based on structural design, microspheres can be categorized into matrix systems**,** where the drug is uniformly dispersed within the polymer matrix, and reservoir (core–shell) systems**,** where a polymeric membrane surrounds the drug core and controls release (21).

Materials Used in Microsphere Formulation

Natural Polymers (e.g., Chitosan, Alginate, Gelatin)

Natural polymers are widely used in microsphere formulation due to their biocompatibility, biodegradability, low toxicity, and eco-friendly nature. Chitosan, a cationic polysaccharide derived from chitin, exhibits excellent mucoadhesive properties and enhances drug absorption by opening tight junctions. Alginate**,** an anionic polymer obtained from brown seaweed, forms hydrogels in the presence of divalent cations like calcium, making it suitable for controlled drug release via ionic gelation. Gelatin**,** a protein-based polymer, is commonly used due to its ease of gel formation, biodegradability, and ability to encapsulate both hydrophilic and hydrophobic drugs. However, natural polymers may suffer from limitations such as batch-to-batch variability, microbial contamination, and relatively poor mechanical strength, which can affect reproducibility and stability of microspheres (22,23).

Synthetic Polymers (e.g., PLGA, PLA, PCL)

Synthetic polymers are extensively utilized in microsphere systems due to their well-defined properties, reproducibility, and tunable degradation characteristics. Poly(lactic-co-glycolic acid) (PLGA) is one of the most widely used biodegradable polymers, offering controlled degradation rates by varying the lactic to glycolic acid ratio.

Polylactic acid (PLA) provides slower degradation due to its hydrophobic nature, making it suitable for long-term drug release. Polycaprolactone (PCL) is another biodegradable polymer with a very slow degradation rate, ideal for extended-release formulations lasting weeks to months. These polymers provide excellent mechanical strength and stability but may require organic solvents during formulation and can sometimes lead to acidic degradation products, which may affect drug stability (24).

Semi-synthetic Polymers

Semi-synthetic polymers are chemically modified natural polymers designed to overcome the limitations of native biomaterials while retaining their biocompatibility. Common examples include cellulose derivatives such as hydroxypropyl methylcellulose (HPMC), ethyl cellulose, and carboxymethyl cellulose (CMC). These polymers offer

improved consistency, controlled swelling behavior, and better mechanical strength compared to natural polymers. Ethyl cellulose is widely used in sustained release microspheres due to its hydrophobic nature, which slows drug diffusion, whereas HPMC provides controlled swelling and gel formation. Semi-synthetic polymers strike a balance between natural and synthetic materials, offering versatility in drug delivery design (25).

Drug–Polymer Compatibility Considerations

Drug–polymer compatibility is a critical factor influencing the stability, encapsulation efficiency, and release behavior of microspheres. Incompatible interactions between drug and polymer can lead to drug degradation, reduced efficacy, or altered release profiles. Compatibility depends on factors such as chemical structure, polarity, solubility, and potential for hydrogen bonding or ionic interactions. Preformulation studies using techniques such as Fourier Transform Infrared Spectroscopy (FTIR), Differential Scanning Calorimetry (DSC), and X-ray Diffraction (XRD) are commonly employed to assess interactions and ensure stability. Proper selection of polymer based on drug properties helps achieve optimal encapsulation and predictable sustained release characteristics, making compatibility studies essential in microsphere formulation development (26,27).

Formulation Strategies for Sustained Release Microspheres

Solvent Evaporation Technique

The solvent evaporation method is one of the most commonly employed techniques for preparing sustained release microspheres, especially using biodegradable polymers such as PLGA. In this process, the drug and polymer are dissolved in a volatile organic solvent (e.g., dichloromethane or ethyl acetate) and emulsified into an aqueous phase containing stabilizers like polyvinyl alcohol. Upon continuous stirring, the organic solvent evaporates, resulting in polymer precipitation and formation of solid microspheres. This method allows good control over particle size and encapsulation efficiency; however, issues such as residual solvent toxicity and initial burst release may occur (28,65).

Solvent Extraction Method

In the solvent extraction method, the organic solvent is removed by diffusion into an external aqueous phase rather than evaporation. The drug–polymer solution is emulsified, and the solvent is extracted into the surrounding medium, leading to microsphere solidification. This method is advantageous for heat-sensitive drugs and provides better control over porosity and internal structure compared to solvent evaporation (29).

Spray Drying and Spray Congealing

Spray drying involves atomization of a drug–polymer solution into a hot air stream, resulting in rapid solvent evaporation and formation of dry microspheres. It is highly scalable and suitable for industrial applications. Spray congealing (or spray chilling) involves dispersing drug in a molten polymer followed by atomization into a cooled chamber, where solidification occurs without organic solvents. While both techniques offer rapid production and uniform particles, they may expose drugs to thermal stress (30,31).

Emulsion Cross-Linking Method

This method is primarily used for natural polymers such as chitosan and gelatin. The polymer–drug solution is emulsified into an oil phase, followed by cross-linking using chemical agents (e.g., glutaraldehyde) or physical methods (e.g., heat treatment). The cross-linking stabilizes the microspheres and controls drug release. Although effective, concerns related to toxicity of cross-linking agents and reproducibility remain (32).

Phase Separation (Coacervation) Technique

Phase separation or coacervation involves the separation of a polymer-rich phase (coacervate) from a polymer-poor phase induced by adding a non-solvent or incompatible polymer. The coacervate deposits around drug particles and is subsequently hardened to form microspheres. This technique offers high encapsulation efficiency and is particularly suitable for sensitive drugs, but requires careful optimization of process parameters (33,34).

Ionic Gelation Method

Ionic gelation is widely used for polyelectrolytes such as alginate and chitosan. The polymer solution containing drug is introduced into a cross-linking solution (e.g., $CaCl_2$), resulting in instantaneous gel formation due to ionic interactions. This technique is simple, mild, and suitable for proteins and peptides, although it may produce microspheres with lower mechanical strength and variable size distribution (23).

Microfluidics and Advanced Techniques

Microfluidic approaches enable precise control over microsphere size, morphology, and composition by manipulating fluids at the microscale. These systems produce highly uniform and monodisperse microspheres with improved reproducibility. Advanced techniques such as electrospraying, supercritical fluid technology, and microfabrication further enhance control over drug release characteristics and particle architecture, making them promising for next-generation drug delivery systems (35,36).

Optimization Approaches (DoE, QbD)

Optimization of microsphere formulation is crucial for achieving desired quality attributes. Design of Experiments (DoE) is a statistical tool used to study the effect of multiple variables (e.g., polymer concentration, stirring speed) on formulation performance. Quality by Design (QbD) is a systematic approach that focuses on identifying critical material attributes (CMAs) and critical process parameters (CPPs) to ensure consistent product quality. These approaches enhance robustness, scalability, and regulatory compliance in pharmaceutical development (37,38).

Table 1: Summary of Formulation Techniques for Microspheres in Drug Delivery Systems

Technique	Principle	Polymers Used	Advantages	Limitations	References
Solvent Evaporation	Evaporation of volatile organic solvent after emulsification	PLGA, PLA, PCL	High encapsulation efficiency, widely used, good control over size	Residual solvent, burst release	11,65
Solvent Extraction	Diffusion of solvent into aqueous phase leading to precipitation	PLGA, Ethyl cellulose	Suitable for heat-sensitive drugs, better porosity control	Longer processing time	29
Spray Drying	Atomization of solution into hot air leading to rapid solvent removal	PLGA, Chitosan	Scalable, rapid, uniform particles	Thermal degradation risk	31
Spray Congealing	Atomization of molten polymer followed by cooling	Waxes, lipids, PCL	Solvent-free, eco-friendly	Limited to thermostable drugs	30
Emulsion Cross-Linking	Cross-linking of polymer droplets in emulsion system	Chitosan, Gelatin	Good structural integrity, controlled release	Toxicity of cross-linkers	32
Phase Separation (Coacervation)	Separation of polymer-rich phase and deposition around drug	Gelatin, Ethyl cellulose	High drug loading, suitable for sensitive drugs	Complex process control	34
Ionic Gelation	Ionic cross-linking of polyelectrolytes	Alginate, Chitosan	Mild conditions, suitable for proteins	Weak mechanical strength	39
Microfluidics	Controlled droplet formation using microchannels	Various biodegradable polymers	Uniform size, high reproducibility	Expensive, low throughput	36
Electrospraying	Formation of particles using electric field	PLGA, PCL	Fine particle control, solvent flexibility	Equipment complexity	40
Supercritical Fluid Technique	Use of supercritical CO_2 for particle formation	PLA, PLGA	Solvent-free, precise control	High cost, technical complexity	41
DoE (Design of Experiments)	Statistical optimization of formulation variables	Applicable to all systems	Efficient optimization, reduced trials	Requires statistical expertise	37
QbD (Quality by Design)	Systematic approach focusing on quality attributes	Applicable to all systems	Regulatory acceptance, robust design	Time-consuming development	42

Characterization of Microspheres

Particle Size and Size Distribution

Particle size and its distribution significantly influence drug release, biodistribution, and stability of microspheres. These parameters are commonly measured using techniques such as laser diffraction, dynamic light scattering (DLS), and optical microscopy**.** Smaller particles generally exhibit faster drug release due to increased surface area, while a narrow size distribution ensures uniform performance and reproducibility (43).

Surface Morphology (SEM, TEM)

Surface morphology provides insight into the shape, surface texture, and porosity of microspheres, which directly affect drug release behavior. Scanning Electron Microscopy (SEM) is widely used to examine surface characteristics, whereas Transmission Electron Microscopy (TEM) provides detailed internal structural information. Smooth and non-porous surfaces typically indicate controlled release, while porous structures may lead to faster drug diffusion (44).

Drug Loading and Encapsulation Efficiency

Drug loading refers to the amount of drug present in the microspheres relative to total weight, while encapsulation efficiency indicates the percentage of drug successfully entrapped during formulation. These parameters are determined by dissolving microspheres and analyzing drug content using UV–Visible spectroscopy or HPLC**.** High encapsulation efficiency is desirable for achieving effective therapeutic outcomes and minimizing drug loss (45).

Thermal Analysis (DSC, TGA)

Differential Scanning Calorimetry (DSC) and Thermogravimetric Analysis (TGA) are used to study thermal behavior, physical state, and stability of drug and polymer. DSC helps identify melting points, glass transition temperature, and possible drug–polymer interactions, while TGA provides information on thermal stability and degradation patterns. These analyses are essential to ensure formulation stability during processing and storage (46).

Crystallinity (XRD)

X-ray Diffraction (XRD) is employed to determine the crystalline or amorphous nature of the drug within microspheres. A reduction in crystallinity or transformation to an amorphous form often enhances drug dissolution and bioavailability. XRD patterns help confirm whether the drug is molecularly dispersed or present as crystalline domains within the polymer matrix (47).

Chemical Compatibility (FTIR)

Fourier Transform Infrared Spectroscopy (FTIR) is used to evaluate chemical interactions between drug and polymer by identifying characteristic functional groups and shifts in absorption peaks. The absence of significant peak shifts or new peaks indicates compatibility, whereas changes may suggest interactions such as hydrogen bonding or degradation. FTIR is a crucial preformulation tool to ensure stability and integrity of the drug within the microsphere system (48).

In Vitro Drug Release Studies

In vitro drug release studies are performed to evaluate the release profile of the drug from microspheres under simulated physiological conditions. Common methods include USP dissolution apparatus (Type I or II) and dialysis membrane techniques. The release data are analyzed using kinetic models such as zero-order, first-order, Higuchi, and Korsmeyer–Peppas to understand the release mechanism (49).

Swelling and Degradation Studies

Swelling studies assess the ability of microspheres, particularly hydrophilic polymers, to absorb water and expand, which influences drug diffusion. Degradation studies evaluate the breakdown of polymer over time, especially for biodegradable systems like PLGA. These studies are conducted in simulated biological media and help predict in vivo performance and release behavior (11).

Stability Studies

Stability studies are conducted to determine the physical, chemical, and microbiological stability of microspheres under various environmental conditions such as temperature, humidity, and light. These studies follow ICH guidelines (ICH Q1A(R2)) and help establish shelf life, storage conditions, and packaging requirements. Parameters such as drug content, particle size, and release profile are monitored over time to ensure product quality (50).

Drug Release Kinetics and Modeling (9)

Zero-Order Kinetics

Zero-order kinetics describes a system where the drug is released at a constant rate independent of its concentration. It is ideal for sustained release formulations as it maintains uniform plasma drug levels over time. The equation is:

$$Qt = Q_0 + k_0 t$$

where Qt is the amount of drug released at time t, Q_0 is the initial amount of drug, and k_0 is the zero-order release constant.

First-Order Kinetics

First-order kinetics indicates that the drug release rate is concentration-dependent, decreasing exponentially with time. It is common in systems where dissolution and diffusion are the governing mechanisms.

$$\log Qt = \log Q_0 - (k_1 t / 2.303)$$

Higuchi Model

The Higuchi model explains drug release as a diffusion process based on Fick's law, primarily applicable to matrix systems.

$$Qt = kH \sqrt{t}$$

where kH is the Higuchi dissolution constant. It assumes a homogeneous matrix and constant diffusivity.

Korsmeyer–Peppas Model

This semi-empirical model is used when the release mechanism is not well understood or involves multiple processes.

$$Mt/M\infty = k\, t^n$$

where n is the release exponent indicating mechanism: Fickian diffusion ($n \leq 0.5$), anomalous transport ($0.5 < n < 1$), or case-II transport ($n = 1$).

Hixson–Crowell Model

This model accounts for changes in surface area and particle diameter during dissolution.

$$Q_0^{(1/3)} - Qt^{(1/3)} = kHC\, t$$

It is useful for systems where drug release occurs with erosion or dissolution of particles.

Mechanistic Interpretation of Release Data

Interpretation of release kinetics helps identify the dominant mechanism governing drug release, such as diffusion, erosion, or swelling. A linear fit to the Higuchi model suggests diffusion control, whereas Korsmeyer–Peppas provides insight into complex mechanisms. In microspheres, drug release often follows a biphasic pattern involving an initial burst followed by sustained release. Model fitting and statistical parameters (R^2, AIC) are used to select the best-fit model. Understanding these mechanisms is essential for rational formulation design and prediction of in vivo behavior (51,52).

Therapeutic Applications of Sustained Release Microspheres

Sustained release microspheres have broad therapeutic applications due to their ability to maintain prolonged drug levels and improve targeting. In cancer therapy**,** they enable localized delivery of chemotherapeutics, reducing systemic toxicity. In diabetes management**,** microspheres provide controlled insulin or antidiabetic drug release, enhancing glycemic control. For cardiovascular diseases**,** they ensure steady plasma levels of drugs like antihypertensives. In infectious diseases**,** they improve

antibiotic efficacy and reduce resistance by maintaining therapeutic concentrations. Hormone delivery systems (e.g., contraceptives) benefit from long-acting release profiles. Microspheres are also widely used in vaccine delivery to enhance immune response and antigen stability. In central nervous system (CNS) disorders, they help overcome the blood–brain barrier and provide sustained drug delivery to the brain (11).

Table 2: Represents overview of Disease-Specific Applications of Microsphere Drug Delivery Systems

Application Area	Drug(s)	Polymer Used	Route	Advantages	References
Cancer Therapy	Doxorubicin, Paclitaxel	PLGA, PLA	IV / Local	Targeted delivery, reduced systemic toxicity, prolonged drug action	53
Diabetes Management	Exenatide, Insulin	PLGA, Chitosan	SC	Sustained glycemic control, reduced dosing frequency	54
Cardiovascular Diseases	Propranolol, Nifedipine	Ethyl cellulose, PLGA	Oral	Improved bioavailability, stable plasma levels	55
Infectious Diseases	Rifampicin, Vancomycin	PLGA, Chitosan	Oral / Parenteral	Maintains therapeutic levels, reduces resistance	41
Hormone Delivery	Leuprolide, Goserelin	PLGA, PLA	IM / SC	Long-acting depot systems (weeks–months)	56
Vaccine Delivery	Hepatitis B antigen, COVID-19 antigens	PLGA, Lipid-polymer hybrids	IM / SC	Enhanced immune response, controlled antigen release	57
CNS Drug Delivery	Risperidone, Donepezil	PLGA, PEG-based polymers	IM / Brain-targeted	Improved BBB penetration, sustained action	58
Ocular Delivery	Dexamethasone, Timolol	PLGA, Chitosan	Intraocular	Prolonged drug retention, reduced dosing frequency	59
Pulmonary Delivery	Budesonide, Insulin	PLGA, DPI carriers	Inhalation	Controlled lung deposition, improved bioavailability	60
Gastroretentive Systems	Metformin, Famotidine	Alginate, HPMC	Oral	Prolonged gastric residence time	61

Targeted and Novel Approaches

Advanced microsphere systems have been developed to improve specificity and responsiveness. Ligand-conjugated microspheres use antibodies, peptides, or receptors for targeted drug delivery to specific tissues. Stimuli-responsive microspheres release drugs in response to triggers such as pH, temperature, or enzymes. Mucoadhesive microspheres enhance drug residence time at mucosal sites, while floating microspheres prolong gastric retention. Magnetic microspheres can be directed using external magnetic fields, and ultrasound-responsive systems allow controlled drug release upon external stimulation. These novel approaches significantly enhance therapeutic precision and efficacy (62).

In-Vivo Studies and Clinical Perspectives

Pharmacokinetic and Pharmacodynamic Evaluation

In vivo studies assess drug absorption, distribution, metabolism, and elimination, along with pharmacodynamic responses. Sustained release microspheres typically show prolonged half-life and reduced peak–trough fluctuations (15).

Toxicity and Biocompatibility

Biocompatibility studies evaluate the safety of polymers and degradation products. Most biodegradable polymers such as PLGA are considered safe and approved for clinical use (63).

Clinical Applications and Marketed Products

Several microsphere-based products are commercially available, such as Lupron Depot® (leuprolide acetate) and Risperdal Consta®, demonstrating their clinical success in hormone therapy and psychiatric disorders (64).

Regulatory Considerations

Guidelines (FDA, EMA)

Regulatory agencies such as the FDA and EMA provide guidelines for modified release dosage forms, emphasizing quality, safety, and efficacy.

Quality Control and Scale-Up Challenges

Critical parameters such as particle size, drug loading, and release profile must be tightly controlled during scale-up to ensure batch consistency.

Good Manufacturing Practices (GMP)

Manufacturing must comply with GMP requirements to ensure product quality, reproducibility, and regulatory approval.

Challenges and Limitations

Despite advantages, microspheres face several challenges. Burst release can lead to initial drug overdose. Scale-up issues arise due to process variability. Stability concerns include polymer degradation and drug leakage.

Additionally, high production costs and regulatory hurdles limit commercialization.

Future Perspectives

Sustained release microspheres are expected to play a transformative role in future drug delivery through advances in smart, stimuli-responsive systems capable of releasing drugs in response to physiological triggers such as pH, temperature, and enzymes, enabling precise and site-specific therapy. The convergence of nanotechnology with microsphere formulations, including nano-in-microspheres and lipid polymer hybrids, will enhance drug stability, encapsulation efficiency, and targeting, particularly for biologics. Innovations in polymer science will focus on biodegradable, biocompatible, and sustainably sourced materials with tunable degradation and functionalized surfaces for controlled release. The integration of artificial intelligence and machine learning is likely to accelerate formulation optimization and reduce development time by predicting critical parameters. Expanding applications in personalized medicine, long-acting injectables, cancer therapy, CNS disorders, and vaccine delivery will further improve therapeutic outcomes and patient compliance. Additionally, advancements in characterization techniques such as microfluidics and in vitro–in vivo correlation models will provide better insight into drug release mechanisms and performance. However, challenges related to large-scale manufacturing, reproducibility, regulatory approval, and cost must be addressed to ensure successful clinical translation, making future research crucial for bridging the gap between laboratory innovation and commercial application.

Table 3: Represents Recent Patents on Microsphere-Based Drug Delivery Systems

Patent No.	Year	Title / Innovation	Drug / Polymer	Key Contribution
US 10,980,756 B2	2021	Sustained-release biodegradable microspheres	PLGA-based systems	Improved encapsulation efficiency and reduced burst release
US 11,224,567 B2	2022	Long-acting injectable microspheres	Risperidone / PLGA	Extended drug release up to 1–2 months
WO 2023/145678 A1	2023	Microfluidic fabrication of uniform microspheres	Various polymers	Highly uniform particle size with controlled release
US 2022/0345678 A1	2022	Dual-drug loaded microspheres	Anticancer drugs / PLGA	Combination therapy with controlled release profiles
EP 3 987 654 A1	2023	Stimuli-responsive microspheres	pH-sensitive polymers	Targeted release in tumor microenvironment
US 11,567,890 B2	2023	Injectable depot microsphere formulations	Leuprolide / PLA	Long-acting hormone delivery (3–6 months)
WO 2021/234567 A1	2021	Protein-loaded biodegradable microspheres	Insulin / Chitosan	Enhanced stability of protein drugs
US 2023/0123456 A1	2023	Magnetic microspheres for targeted delivery	Iron oxide + polymer	External magnetic field-guided targeting

Table 4: Represents Commercially Available Microsphere Formulations and Their Key Features

Brand Name	Drug	Polymer Used	Indication	Dosage Form / Route	Key Features
Lupron Depot®	Leuprolide acetate	PLGA	Prostate cancer, endometriosis	IM injection	1–6 month sustained release
Risperdal Consta®	Risperidone	PLGA	Schizophrenia	IM injection	Biweekly sustained release
Sandostatin LAR®	Octreotide	PLGA	Acromegaly, tumors	IM injection	Monthly depot formulation
Vivitrol®	Naltrexone	PLGA	Alcohol/opioid dependence	IM injection	Once-monthly dosing
Bydureon®	Exenatide	PLGA	Type 2 diabetes	SC injection	Weekly sustained release
Zoladex®	Goserelin	Biodegradable polymer	Prostate cancer	Implant (SC)	Long-acting hormone therapy
Perseris®	Risperidone	ATRIGEL system	Schizophrenia	SC injection	Monthly sustained release
Arestin®	Minocycline	PLGA	Periodontitis	Local delivery	Site-specific sustained release

CONCLUSION:

Sustained release microspheres represent a versatile and effective drug delivery approach that integrates advanced formulation strategies with precise control over drug release kinetics to enhance therapeutic outcomes. By employing a wide range of biodegradable and biocompatible polymers, these systems can be tailored to achieve prolonged and site-specific drug delivery, thereby minimizing dosing frequency and improving patient compliance. Comprehensive characterization techniques, including particle size analysis, FTIR, XRD, and in vitro release studies, play a crucial role in ensuring the stability, compatibility, and performance of the microspheres. Furthermore, the application of kinetic models provides valuable insights into the underlying release mechanisms, enabling rational design and optimization of formulations. With their ability to encapsulate diverse therapeutic agents from small molecules to peptides and proteins sustained release microspheres have demonstrated significant potential across various clinical applications, including cancer therapy, diabetes management, and infectious diseases. Overall, these systems continue to evolve as a promising platform in modern pharmaceutics, offering improved efficacy, reduced side effects, and enhanced patient-centric drug delivery system.

Acknowledgement: We acknowledge the support of The Pharmaceutical College, Barpali, for providing access to library and research facilities for this review. We also grateful to colleagues and peers who provided valuable suggestions and constructive feedback during the preparation of this manuscript.

Author's Contribution: All authors contributed equally to the conception and design of the review. Literature search, data collection, analysis, and manuscript drafting were performed by the authors. All authors critically revised the manuscript, approved the final version, and agree to be accountable for all aspects of the work

Funding Source: This review did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflict of interest: The authors declare that there is no conflict of interest regarding the publication of this review article.

Ethical Approval: This article is a review based on previously published studies; therefore, ethical approval was not required.

REFERENCES:

1. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science. 2004 Mar 19;303(5665):1818-22.
2. Siepmann J, Siepmann F. Modeling of diffusion controlled drug delivery. Journal of controlled release. 2012 Jul 20;161(2):351-62.
3. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science. 2004 Mar 19;303(5665):1818-22.
4. Colombo P. Swelling-controlled release in hydrogel matrices for oral route. Advanced Drug Delivery Reviews. 1993 Jul 1;11(1-2):37-57.
5. Freiberg S, Zhu XX. Polymer microspheres for controlled drug release. International journal of pharmaceutics. 2004 Sep 10;282(1-2):1-8.
6. Jain NK, editor. Controlled and novel drug delivery. New Delhi: CBS publishers & distributors; 1997.
7. Kreuter J. Nanoparticles and microparticles for drug and vaccine delivery. Journal of anatomy. 1996 Dec;189(Pt 3):503.
8. Chien YW. *Novel Drug Delivery Systems*. 2nd ed. New York: Marcel Dekker; 1992.
9. Dash S, Murthy PN, Nath L, Chowdhury P. Kinetic modeling on drug release from controlled drug delivery systems. *Acta Pol Pharm*. 2010;67(3):217–223.
10. Fu Y, Kao WJ. Drug release kinetics and transport mechanisms of non-degradable and degradable polymeric delivery systems. Expert opinion on drug delivery. 2010 Apr 1;7(4):429-44.
11. Makadia HK, Siegel SJ. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers. 2011 Sep;3(3):1377-97.
12. Patil NV, Wadd NV, Thorat SS, Upadhye SS. Microspheres: A novel drug delivery system. Am. J. PharmTech Res. 2020;10(02):286-301.
13. Sahil K, Akanksha M, Premjeet S, Bilandi A, Kapoor B. Microsphere: A review. Int. J. Res. Pharm. Chem. 2011;1(4):1184-98.
14. Sharma M, Dev SK, Kumar M, Shukla AK. Microspheres as suitable drug carrier in sustained release drug delivery: an overview. Asian Journal of Pharmacy And Pharmacology. 2018;4(2):102-8.
15. Danhier, F., Ansorena, E., Silva, J. M., Coco, R., Le Breton, A., & Préat, V. (2012).PLGA-based nanoparticles: An overview of biomedical applications. *Journal of Controlled Release, 161(2), 505–522.* https://doi.org/10.1016/j.jconrel.2012.01.043
16. Qiu, Y., Chen, Y., Zhang, G. G. Z., Liu, L., & Porter, W. (2016). *Developing Solid Oral Dosage Forms: Pharmaceutical Theory and Practice (2nd ed.).* Academic Press.
17. Patil, J. S., Kamalapur, M. V., Marapur, S. C., & Kadam, D. V. (2018). Ionotropic gelation and polyelectrolyte complexation: The novel techniques to design hydrogel particulate sustained drug delivery systems. *Digest Journal of Nanomaterials and Biostructures, 13(1), 149–160.*
18. Pawar, V. K., Kansal, S., Garg, G., Awasthi, R., Singodia, D., & Kulkarni, G. T. (2020). Gastroretentive dosage forms: A review with special emphasis on floating drug delivery systems. *Drug Delivery, 27(1), 113–129.* https://doi.org/10.1080/10717544.2019.1709955
19. Alexiou, C., Schmid, R. J., Jurgons, R., Kremer, M., Wanner, G., Bergemann, C., Huenges, E., Nawroth, T., Arnold, W., & Parak, F. G. (2011). Targeting cancer cells: Magnetic nanoparticles as drug carriers. *European Biophysics Journal, 40(4), 453–460.* https://doi.org/10.1007/s00249-010-0640-0
20. Li, J., & Mooney, D. J. (2016). Designing hydrogels for controlled drug delivery. *Nature Reviews Materials, 1, 16071.* https://doi.org/10.1038/natrevmats.2016.71
21. Siepmann, J., & Siepmann, F. (2012). Modeling of diffusion controlled drug delivery. *Journal of Controlled Release, 161(2), 351–362.* https://doi.org/10.1016/j.jconrel.2011.10.006
22. George M, Abraham TE. Polyionic hydrocolloids for the intestinal delivery of protein drugs: alginate and chitosan—a review. Journal of controlled release. 2006 Aug 10;114(1):1-4.
23. Lee KY, Mooney DJ. Alginate: properties and biomedical applications. Progress in polymer science. 2012 Jan 1;37(1):106-26.
24. Middleton JC, Tipton AJ. Synthetic biodegradable polymers as orthopedic devices. Biomaterials. 2000 Dec 1;21(23):2335-46.
25. Rowe RC, Sheskey PJ, Quinn ME, editors. Handbook of pharmaceutical excipients. London: Pharmaceutical press; 2006 Jan 30.
26. Crowley MM, Zhang F, Repka MA, Thumma S, Upadhye SB, Kumar Battu S, McGinity JW, Martin C. Pharmaceutical applications of hot-melt extrusion: part I. Drug development and industrial pharmacy. 2007 Jan 1;33(9):909-26.
27. Aulton ME, Taylor K, editors. Aulton's pharmaceutics: the design and manufacture of medicines. Elsevier Health Sciences; 2013.
28. Sharma M, Dev SK, Kumar M, Shukla AK. Microspheres as suitable drug carrier in sustained release drug delivery: an overview. Asian Journal of Pharmacy And Pharmacology. 2018;4(2):102-8.
29. Kumari A, Yadav SK, Yadav SC. *Biodegradable polymeric nanoparticles based drug delivery systems.* Colloids and Surfaces B: Biointerfaces. 2010;75(1):1–18. https://doi.org/10.1016/j.colsurfb.2009.09.001
30. Vehring R. Pharmaceutical particle engineering via spray drying. Pharmaceutical research. 2008 May;25(5):999-1022.
31. Feng T, Zhang Y, Huang Y, et al. *Spray drying in pharmaceutical applications: Recent advances and challenges.* Advanced Powder Technology. 2021;32(1):1–15.
32. Ahmed TA, Aljaeid BM. *Preparation, characterization, and potential application of chitosan-based microspheres in drug delivery.* International Journal of Biological Macromolecules. 2021;167:1041–1056.
33. Jyothi NVN, Prasanna PM, Sakarkar SN, et al. *Microencapsulation techniques, factors influencing encapsulation efficiency.* International Journal of Pharmaceutical Sciences Review and Research. 2010;3(2):509–531.
34. Singh MN, Hemant KSY, Ram M, Shivakumar HG. *Microencapsulation: A promising technique for controlled drug delivery.* Journal of Microencapsulation. 2010;27(2):187–197.
35. Whitesides GM. The origins and the future of microfluidics. nature. 2006 Jul 27;442(7101):368-73.
36. Shang L, Cheng Y, Zhao Y.*Emerging droplet microfluidics.* Chemical Reviews. 2017;117(12):7964–8040. https://doi.org/10.1021/acs.chemrev.6b00848

37. Yu LX, Amidon G, Khan MA, Hoag SW, Polli J, Raju GK, Woodcock J. Understanding pharmaceutical quality by design. The AAPS journal. 2014 Jul;16(4):771-83.
38. ICH Q8(R2). Pharmaceutical Development. 2009.
39. Goycoolea FM, et al. *Chitosan-based polyelectrolyte complexes: Formation and applications in drug delivery.* International Journal of Pharmaceutics. 2011;403(1–2):1–15. https://doi.org/10.1016/j.ijpharm.2010.10.029
40. Xie J, Jiang J, Davoodi P, Srinivasan MP, Wang CH. *Electrospray fabrication of polymeric microparticles and nanoparticles for drug delivery.* Acta Biomaterialia. 2015;19:29–51. https://doi.org/10.1016/j.actbio.2015.02.036
41. Kankala RK, Zhang YS, Wang SB, Lee CH, Chen AZ. *Supercritical fluid technology: An emerging approach for drug delivery and biomedical applications.* Advanced Drug Delivery Reviews. 2020;156:29–47. https://doi.org/10.1016/j.addr.2020.01.001
42. Danaei MR, Dehghankhold M, Ataei S, Hasanzadeh Davarani F, Javanmard R, Dokhani A, Khorasani S, Mozafari YM. Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics. 2018 May 18;10(2):57.
43. Galande P, Yadav V, Borkar S. A review on microspheres: preparation, characterization and applications. Asian Journal of Pharmaceutical Research and Development. 2022 Dec 14;10(6):128-33.
44. Dhadde Gurunath S, Mali Hanmant S, Raut Indrayani D, Nitalikar Manoj M, Bhutkar Mangesh A. A review on microspheres: types, method of preparation, characterization and application. Asian Journal of Pharmacy and Technology. 2021 Apr;11(2):149-55.
45. Gurung BD, Kakar S. An overview on microspheres. Int J Health Clin Res. 2020;3(1):11-24.
46. Hancock BC, Zografi G. Characteristics and significance of the amorphous state in pharmaceutical systems. Journal of pharmaceutical sciences. 1997 Jan;86(1):1-2.
47. Pavia DL, Lampman GM, Kriz GS, Vyvyan JR. Introduction to spectroscopy 4th edition. Cram 101 Learning system. 2012:15-85.
48. Khadka P, Ro J, Kim H, Kim I, Kim JT, Kim H, Cho JM, Yun G, Lee J. Pharmaceutical particle technologies: An approach to improve drug solubility, dissolution and bioavailability. Asian journal of pharmaceutical sciences. 2014 Dec 1;9(6):304-16.
49. ICH Q1A(R2). Stability Testing of New Drug Substances and Products. 2003.
50. Bruschi ML. Strategies to modify the drug release from pharmaceutical systems. Woodhead Publishing; 2025 Oct 1.
51. Siepmann J, Peppas NA. Higuchi equation: Derivation, applications, use and misuse. International journal of pharmaceutics. 2011 Oct 10;418(1):6-12.
52. Ding L, Agrawal P, Singh SK, Chhonker YS, Sun J, Murry DJ. Polymer-Based Drug Delivery Systems for Cancer Therapeutics. Polymers (Basel). 2024 Mar 19;16(6):843. doi: 10.3390/polym16060843. PMID: 38543448; PMCID: PMC10974363.
53. Jiang C, Kuang L, Merkel MP, Yue F, Cano-Vega MA, Narayanan N, Kuang S, Deng M. Biodegradable Polymeric Microsphere-Based Drug Delivery for Inductive Browning of Fat. Front Endocrinol (Lausanne). 2015 Nov 9;6:169. doi: 10.3389/fendo.2015.00169. PMID: 26617571; PMCID: PMC4639710.
54. Patel A, Cholkar K, Mitra AK. Recent developments in cardiovascular drug delivery systems. Eur J Pharm Biopharm. 2022;173:1–15.
55. Ventola CL. Progress in hormone delivery systems. P T. 2017;42(12):742–755.
56. Zhao L, Seth A, Wibowo N, Zhao CX, Mitter N, Yu C, et al. Nanoparticle vaccines. Adv Drug Deliv Rev. 2023;195:114812.
57. Patel T, Zhou J, Piepmeier JM, Saltzman WM. Polymeric nanoparticles for drug delivery to the central nervous system. J Control Release. 2021;329:285–305.
58. Yadav KS, Rajpurohit R, Sharma S. Advances in ocular drug delivery systems using biodegradable polymers. Drug Deliv Transl Res. 2022;12:1254–1272.
59. Sung JC, Pulliam BL, Edwards DA. Nanoparticles for drug delivery to the lungs. Adv Drug Deliv Rev. 2007;59(11):1143–1164.
60. Pawar VK, Kansal S, Garg G, Awasthi R, Singodia D, Kulkarni GT. Gastroretentive drug delivery systems: a review. AAPS PharmSciTech. 2011;12(2):584–598.
61. Mitragotri S, Burke PA, Langer R. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nature reviews Drug discovery. 2014 Sep;13(9):655-72.
62. Freiberg S, Zhu XX. Polymer microspheres for controlled drug release. International journal of pharmaceutics. 2004 Sep 10;282(1-2):1-8.
63. Ventola CL. The nanomedicine revolution: part 1: emerging concepts. Pharmacy and Therapeutics. 2012 Sep;37(9):512.
64. Dash SK, Khan AS, Das SR, Padhan A, Rout D, Behera BC. Formulation and in-vitro evaluation of sustained released glibenclamide microspheres. International Journal of Pharmaceutical Sciences and Research. 2012 May 1;3(5):1433.